Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX +
Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal
Junction (GEJ) and stomach.